Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities
- PMID: 28967957
- DOI: 10.1093/ecco-jcc/jjx081
Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities
Abstract
Background and aim: Immune checkpoint inhibitors targeting CTLA-4 and PD-1 improve survival in cancer patients but may induce immune-related adverse events, including colitis. The immunological characteristics of anti-CTLA-4 [αCTLA-4]- and anti-PD-1 [αPD-1]-related colitis have been poorly described. The aim of the present study was to compare the immunological and histological characteristics of αCTLA-4-induced colitis and αPD-1-induced colitis.
Methods: Colonic biopsies from patients with αCTLA-4-induced colitis, αPD-1-induced colitis, and inflammatory bowel disease [IBD] were analysed by immunohistochemistry and flow cytometry. Tumour necrosis factor alpha [TNFα] concentration was assessed in biopsy supernatants.
Results: CD8+ T cells were found in the lamina propria and epithelium in αPD-1-induced colitis, whereas CD4+ T cells were found in the lamina propria in αCTLA-4-induced colitis. No or low intraepithelial lymphocytes were observed in αCTLA-4-induced colitis. No difference in numbers of mucosal regulatory T cells was observed between αCTLA-4- or αPD-1-induced colitis and IBD patients. Higher numbers of activated ICOS+ conventional CD4+ T cells were observed in αCTLA-4-induced colitis compared with patients with IBD. Among ICOS+CD4+ T cells, conventional CD4+ T cells were the main T cell population in patents with αCTLA-4-induced colitis, whereas Treg cells were predominant in IBD or αPD-1-induced colitis. High mucosal TNFα concentrations were observed in αCTLA-4-induced colitis. Low mucosal TNFα concentrations were associated with steroid sensitivity.
Conclusions: These observations show that αCTLA-4- and αPD-1-induced colitis have distinct immunological characteristics. Mucosal TNFα concentration might detect patients at risk of developing corticosteroid resistance after CTLA-4 blockade.
Keywords: Anti-CTLA-4; anti-PD-1; colitis; immune checkpoint blockade; immune-related adverse events.
Copyright © 2017 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com
Similar articles
-
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors.J Immunother Cancer. 2022 Jan;10(1):e003488. doi: 10.1136/jitc-2021-003488. J Immunother Cancer. 2022. PMID: 35058324 Free PMC article.
-
IL-7/αIL-7 mAb M25 immunocomplexes expand CD8+ T cells but paradoxically abrogate the antitumor activity of CTLA-4 and PD-1 blockage.Cytokine. 2020 Sep;133:155174. doi: 10.1016/j.cyto.2020.155174. Epub 2020 Jun 26. Cytokine. 2020. PMID: 32599539
-
Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis.Nat Med. 2024 May;30(5):1349-1362. doi: 10.1038/s41591-024-02895-x. Epub 2024 May 9. Nat Med. 2024. PMID: 38724705 Free PMC article.
-
Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.Dan Med J. 2015 Jan;62(1):B4973. Dan Med J. 2015. PMID: 25557335 Review.
-
Checkpoint inhibitor colitis: a new model of inflammatory bowel disease?Curr Opin Gastroenterol. 2018 Nov;34(6):377-383. doi: 10.1097/MOG.0000000000000482. Curr Opin Gastroenterol. 2018. PMID: 30157044 Review.
Cited by
-
The multifaceted roles of common gut microbiota in immune checkpoint inhibitor-mediated colitis: From mechanism to clinical application.Front Immunol. 2022 Sep 14;13:988849. doi: 10.3389/fimmu.2022.988849. eCollection 2022. Front Immunol. 2022. PMID: 36189293 Free PMC article. Review.
-
Clinical characterization of colitis arising from anti-PD-1 based therapy.Oncoimmunology. 2018 Oct 31;8(1):e1524695. doi: 10.1080/2162402X.2018.1524695. eCollection 2019. Oncoimmunology. 2018. PMID: 30546965 Free PMC article.
-
Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management.Int J Mol Sci. 2023 Jul 15;24(14):11504. doi: 10.3390/ijms241411504. Int J Mol Sci. 2023. PMID: 37511260 Free PMC article. Review.
-
Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis.Virchows Arch. 2021 Dec;479(6):1119-1129. doi: 10.1007/s00428-021-03170-x. Epub 2021 Aug 2. Virchows Arch. 2021. PMID: 34338882 Free PMC article.
-
Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities.Front Immunol. 2020 Oct 6;11:2023. doi: 10.3389/fimmu.2020.02023. eCollection 2020. Front Immunol. 2020. PMID: 33123120 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials